Intercept Pharma To Present Addl. Data From Phase 3 Trial Of OCA

(RTTNews) - Intercept Pharmaceuticals, Inc. (ICPT) Saturday said it will present new data analyses from its first Phase 3 trial of obeticholic acid or OCA, in patients with primary biliary cirrhosis.

OCA is the company's lead experimental drug, indicated for the treatment of common liver diseases.

In a session at the American Association for the Study of Liver Disease, the company will present six posters, which will have new analyses of data from the POISE trial in two decades.

The data will provide insights into new subgroup analyses of the treatment effect for OCA across a range of patient characteristics associated with greater risk of adverse clinical outcomes. It will also describe the long-term safety and efficacy results from open-label treatment of OCA for over four years.

Earlier in March, the group reported that OCA had met its primary endpoint with high statistical significance.